Prostate Cancer Biomarker Enrichment and Treatment Selection

Titre officiel

Prostate Cancer Biomarker Enrichment and Treatment Selection (PC-BETS) Study

Sommaire:

Le dépistage préalable à l’étude vise à déterminer les anomalies de l’ADN ou les biomarqueurs.

Description de l'essai

Primary Outcome:

  • Clinical benefit rate defined as proportion of patients who had PSA decline ≥ 50%, complete or partial objective response, or Stable disease for ≥ 12 weeks.
Secondary Outcome:
  • Measure effect of each study drug on PSA decline
  • Measure objective response as determined by RECIST 1.1 criteria
  • Number and severity of adverse events
  • Measure effect of each study drug on time to PSA progression
This testing will be done on a samples of blood to see whether or not patients are eligible to take part in one of the main studies. Each study will be looking at what effects a new drug or drugs has on prostate cancer and will also be looking at the side effects of treatment. The purpose of the main studies is to see if the biomarkers that were identified screening samples can help predict which patients are most likely to be helped by that drug or drugs and to see how the cancer cells respond to treatment.

Voir cet essai sur ClinicalTrials.gov

Intéressé(e) par cet essai?

Imprimez cette page et apportez-la chez votre médecin pour discuter de votre admissibilité à cet essai et des options de traitement. Seul votre médecin peut vous recommander pour un essai clinique.

Ressources

Société canadienne du cancer

Ces ressources sont fournies en partenariat avec Société canadienne du cancer